Cobiprostone

DB05514InvestigationalSmall molecule

Investigated for use/treatment in cystic fibrosis.

Mechanism: Pharmacologically active on Chloride channel protein 2
Curator reviewed
Primary indication: Investigated for use/treatment in cystic fibrosis.Curator reviewed
Formula / weight: C₂₁H₃₄F₂O₅ · 404.495 g/mol (avg)
Code names: SPI-8811

Resolves to

Compound

Structure

InChIKeySDDSJMXGJNWMJY-BRHAQHMBSA-NSMILESCC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(O)=O)O1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cobiprostone, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.